On Sept. 4, 2020, Roche announced that the cobasﾮ SARS-CoV-2 & Influenza A/B Test for use on the cobasﾮ 6800/8800 Systems had received Emergency Use Authorization (EUA) from the FDA. This test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients suspected by their healthcare provider of having respiratory viral infection consistent with COVID-19. Additionally, it is available in markets accepting the CE mark.